Erythrodermic Psoriasis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for erythrodermic psoriasis. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
4
Active US patents
41/100
Avg vulnerability
$291M
Annual revenue covered

Originators in Erythrodermic Psoriasis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating erythrodermic psoriasis. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sotyktu
DEUCRAVACITINIB
 Bristol-Myers Squibb 4 41 $291M 2033-11-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12521390 Sotyktu method of use 58 2043-02-11
RE47929 Sotyktu method of use 53 2033-11-07
11021475 Sotyktu method of use 53 2033-11-07
10000480 Sotyktu composition of matter 0 2033-11-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10000480 Sotyktu composition of matter 0 2033-11-07
RE47929 Sotyktu method of use 53 2033-11-07
11021475 Sotyktu method of use 53 2033-11-07
12521390 Sotyktu method of use 58 2043-02-11

Related